Plain-English translation of NCT07635316 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This is a retrospective study — meaning researchers will look back at existing medical records and insurance data from patients who have been newly diagnosed with gastroenteropancreatic neuroendocrine tumors (GEP-NETs, a rare type of cancer). The study will track what treatments patients received, including lutetium Lu 177 dotatate, CAPTEM (chemotherapy), cabozantinib, and other available therapies, and examine how well these treatments worked and what happened to patients over time.
Neuroendocrine tumors are rare, and doctors need better information about which treatments work best for different patients and at what stages of the disease. By studying real-world treatment patterns and outcomes, researchers can help guide future treatment decisions and improve care for patients with this condition.
You likely qualify if…
You likely don't qualify if…
This is not an active treatment study — you will not receive any new medication or undergo any procedures. Instead, researchers will review your existing medical records, insurance claims, and prescription history to see what treatments you received for your neuroendocrine tumor and track your health outcomes over time. The study involves no visits, tests, or additional burden on you beyond allowing researchers access to your medical data.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
United States
Sponsor
Novartis Pharmaceuticals
Enrollment target
~4,023 participants
Started
June 2026
Primary completion
February 2027
Age range
18 Years – 110 Years
Last updated on clinicaltrials.gov in July 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Novartis Pharmaceuticals
Novartis Pharmaceuticals
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.